Jump Financial LLC Boosts Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

Jump Financial LLC increased its position in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 862.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 239,933 shares of the company's stock after buying an additional 214,993 shares during the quarter. Jump Financial LLC owned 0.31% of Kura Oncology worth $2,090,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of KURA. Jane Street Group LLC lifted its position in Kura Oncology by 36.7% in the third quarter. Jane Street Group LLC now owns 126,085 shares of the company's stock valued at $2,464,000 after purchasing an additional 33,848 shares during the last quarter. Barclays PLC grew its position in Kura Oncology by 104.5% during the third quarter. Barclays PLC now owns 165,484 shares of the company's stock valued at $3,234,000 after buying an additional 84,563 shares during the period. Geode Capital Management LLC grew its position in Kura Oncology by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock valued at $34,798,000 after buying an additional 41,535 shares during the period. Franklin Resources Inc. grew its position in Kura Oncology by 1.5% during the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock valued at $28,687,000 after buying an additional 23,113 shares during the period. Finally, JPMorgan Chase & Co. grew its position in Kura Oncology by 0.8% during the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company's stock valued at $7,997,000 after buying an additional 3,092 shares during the period.

Kura Oncology Stock Down 0.6 %

NASDAQ KURA traded down $0.04 on Thursday, hitting $6.33. 200,616 shares of the stock were exchanged, compared to its average volume of 1,143,257. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $23.48. The company has a market cap of $511.32 million, a PE ratio of -2.70 and a beta of 0.83. The company has a 50-day moving average price of $6.95 and a 200-day moving average price of $10.21.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. Sell-side analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Insider Transactions at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of the company's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the company's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares of the company's stock, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,729 shares of company stock worth $92,307. 6.40% of the stock is currently owned by insiders.

Analysts Set New Price Targets

KURA has been the subject of a number of recent analyst reports. StockNews.com upgraded shares of Kura Oncology from a "hold" rating to a "buy" rating in a research report on Friday, April 4th. JMP Securities restated a "market outperform" rating and set a $28.00 target price on shares of Kura Oncology in a research report on Thursday, February 6th. Scotiabank dropped their target price on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research report on Wednesday, January 8th. BTIG Research lowered Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday, February 6th. Finally, UBS Group lowered their price target on Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $25.50.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.